January 28, 2013

An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone.

.   .   

The OSCAR study was a multicenter, open-label RCT carried out in Japanese elderly hypertensive patients. Patients were randomized to angiotensin II receptor blocker (ARB) dose up-titration versus an ARB plus calcium channel blocker combination.

In the pre-specified subgroup of patients with CKD, more primary events (a composite of cardiovascular events and noncardiovascular death) occurred in the high-dose ARB group than in the combination group.

Related Articles:

Chronic Kidney Disease, Hypertension

Comments are closed.